title: [Effect of probucol on cardiac electrophysiology in anginal patients with hyperlipidemia and diabetes mellitus type II].
abstract: OBJECTIVE
  To investigate effects of a hypolipidemic drug with antioxidant action probucol on electrophysiological parameters of the heart in patients with ischemic heart disease (IHD), stable angina (SA), hyperlipoproteinemia (HLP) and diabetes mellitus (DM) type II.
  
  
  METHODS
  The trial entered 48 IHD patients (11 males and 37 females) aged 47-73 years with SA functional class II and III (39.4 and 60.6%, respectively), secondary HLP (mean group total cholesterol 6.5 +/- 0.17 mmol/l), DM type II (mean fast glucose 7.7 +/- 1.8 mmol/l) and obesity (mean body mass index 29.7 +/- 2.2 kg/m2). Transesophageal pacing of the left ventricle was conducted in all the patients before probucol treatment and 18 hours, 1 month and 3 months after it.
  
  
  RESULTS
  Probucol (a single dose 500 mg) significantly reduced the time of recovery of sinus node function. Three months of probucol administration in a dose 1000 mg/day enhanced pacemaker activity of the sinus node.
  
  
  CONCLUSIONS
  In addition to a beneficial effect on lipid metabolism (a decrease of total cholesterol by 13.4%, LDLP cholesterol by 15.2%, triglycerides by 15.8%), probucol enhanced pacemaker activity of the sinus node. This makes it perspective in patients with sinus node dysfunction. Caution is necessary in prescribing probucol to patients with supraventricular tachycardia caused by re-entry mechanism.
authors.forename: V V
authors.initials: VV
authors.lastname: Anikin
authors.forename: V V
authors.initials: VV
authors.lastname: Savin
authors.forename: V P
authors.initials: VP
authors.lastname: Lupanov
authors.forename: R A
authors.initials: RA
authors.lastname: Razygraev
mesh_terms: D000368:Aged; D000787:Angina Pectoris / Q000150:complications / Q000503:physiopathology* / Q000628:therapy; D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood; D001786:Blood Glucose / Q000378:metabolism; D015992:Body Mass Index; D002304:Cardiac Pacing, Artificial; D008078:Cholesterol, LDL / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications*; D015716:Electrocardiography, Ambulatory / Q000187:drug effects*; D005260:Female; D006352:Heart Ventricles / Q000187:drug effects / Q000503:physiopathology; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000150:complications* / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000150:complications; D011341:Probucol / Q000627:therapeutic use*; D020127:Recovery of Function / Q000187:drug effects*; D014280:Triglycerides / Q000097:blood
chemical_list: D000924:Anticholesteremic Agents; D015415:Biomarkers; D001786:Blood Glucose; D008078:Cholesterol, LDL; D014280:Triglycerides; D011341:Probucol